🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Technology Sector SEC Filings — May 13, 2026

Across 32 filings in the USA S&P 500 Technology stream (broadly including software, AI, biotech tech, and related), sentiment is predominantly mixed (12/32 filings), with 6 negative and 4 positive, reflecting revenue growth in key tech names like Cisco (+12% YoY to $15.8B) and Formula Systems (+18% YoY to $2.6B) offset by declines in niche players like Planet 13 (-24.8% YoY) and CareView (-2% YoY). Period-over-period trends show 7/15 quarterly reporters with YoY revenue growth averaging +55% (outliers Dyadic +182%, MultiSensor AI +38%), but margins compressed in 5/10 (e.g., Cisco -200bps to 63.6%, MultiSensor -2% to 57%); net losses narrowed in 8/12 biotechs via cost cuts (Adicet R&D -23%, G&A -42%) and cash infusions (Immunic +$187M, Altimmune +$79M net). Forward-looking highlights include Cisco's raised FY2026 revenue guidance to $62.8-63.0B and AI infra to $4B, plus biotech catalysts like Adicet's prula-cel updates mid-2026. Capital allocation favors dividends (Cisco $0.42/share, Atmus $0.055/share), while 13F filings (7/32) reveal stable institutional tech exposure (e.g., Acadian's $3.89B Apple). Portfolio-level theme: Tech growth resilient amid biotech funding boom, but cash burns and margin pressures signal caution; actionable now: Buy Cisco on guidance raise, monitor biotechs for trial data.

11 high priority 21 medium 32 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 13, 2026

Across 32 filings from NASDAQ-100 related entities, Q1 2026 results reveal mixed performance with standout revenue growth in tech (Cisco +12% YoY to $15.8B) and biotechs/specialty firms (Dyadic +182% YoY, MultiSensor AI +38% YoY, Intelligent Bio +45% YoY), but persistent net losses and cash burn in 70% of operating companies despite narrowing in 6/12 cases (e.g., Adicet -28% YoY loss). Biotechs dominated with massive cash infusions (Immunic $200M, Altimmune $225M+, Tharimmune $87M), extending runways into 2027-2028, while REITs like Acadia showed robust NOI +19% YoY. Cisco raised FY2026 revenue guidance to $62.8-63.0B (+AI infra to $4B) and declared $0.42 dividend, signaling conviction; SPACs and miners exhibited typical pre-deal losses amid asset builds. Portfolio trends include margin compression (Cisco -200bps gross, MultiSensor -2%) averaging -100bps across 5 reporters, offset by capex discipline and forward catalysts like 5+ clinical readouts H2 2026. Institutional 13Fs (Group One, State Farm, Acadian) show stable mega-cap tech/energy holdings, neutral positioning. Implications: Tactical buys in growth biotechs/tech with catalysts, caution on high-burn explorers/miners.

15 high priority 17 medium 32 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — May 13, 2026

In a very quiet session for activist and institutional activity (only 1 filing, previously covered), Barrow Hanley Mewhinney & Strauss LLC disclosed a passive 6.30% stake in Warner Music Group Corp. (WMG) via Schedule 13G filed May 13, 2026, as of March 31, 2026. This equates to 9,261,674 shares, with 6,782,967 and 2,478,707 held under shared voting and dispositive power, filed under Rule 13d-1(b) as an investment adviser with no intent to influence control. Neutral sentiment reflects stable, ordinary-course holding rather than activist pressure. No period-over-period ownership changes, forward-looking statements, insider trades, capital allocation shifts, or operational metrics were detailed in the enriched data, limiting cross-company trends. The materiality (7/10) underscores moderate significance as confirmatory institutional interest in WMG amid low overall activity. Implications suggest portfolio stability for WMG but no broad sector catalysts or patterns from this single passive disclosure.

1 medium 1 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 13, 2026

Across 50 filings in the USA S&P 500 Financials stream (primarily Q1 2026 10-Qs and 13F-HRs filed May 13, 2026), asset managers dominate with 13F disclosures showing heavy allocations to tech giants (Apple, Amazon, Nvidia, Alphabet topping most portfolios) and broad ETFs, signaling low conviction in pure financials amid diversified strategies. Financial institutions exhibit mixed period-over-period trends: net interest income (NII) growth in banks like Bogota Financial (+23.2% YoY) contrasts with deposit declines (-7.9% QoQ) and modest net income drops (-3.4% YoY), while insurers like UTG Inc surged net income +81% YoY on investment gains and Lincoln National revenues +17.9% YoY despite net losses. Capital allocation leans shareholder-friendly with NB Bancorp completing 5% buyback (cumulative 16% since 2025) and funds like NMF SLF I declaring distributions amid NAV declines. Non-core filings (e.g., oil, pharma) show volatile revenues/losses, but financials highlight resilience in investment income (+14-39% YoY in funds) offset by unrealized depreciation. Portfolio-level: 30+ 13Fs aggregate ~$200B+ in tech/ETF holdings vs sparse financial-specific bets, implying relative underweight in banks/insurers. Key implication: Watch deposit trends and Q2 catalysts for NIM pressure, with buybacks signaling undervaluation.

18 high priority 32 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 13, 2026

Across 50 SEC filings primarily from Q1 2026 10-Qs, 8-Ks, and 13F-HRs (despite Consumer Staples focus, spanning diverse sectors with staples like Colgate-Palmolive, Coca-Cola Consolidated, Kroger, and Newell Brands), overarching themes include robust revenue growth in 12/18 reporting companies averaging +72% YoY (e.g., Momentus +899%, Motorsport +129%, Accelerant +53.5%) offset by widening net losses in 10/18 (avg +25% YoY deeper) due to op-ex inflation (+40% avg YoY). Staples sector showed governance stability with 100% proposal approvals at Colgate, Coca-Cola Cons, and Newell AGMs, alongside Kroger's strong 2025 recap (9% EPS growth, eCommerce profitable). Mixed sentiment dominated (14/50 filings), with positive AGMs (8/12) and neutral 13Fs (9/9 no changes). Forward guidance emerged bullish for Accelerant (FY EWP $5.2B+), ClearPoint ($52-56M rev), highlighting catalysts amid capex and M&A (e.g., Allegiant-Sun Country $140M synergies). Capital allocation leaned shareholder-friendly (buybacks at Accelerant, distributions +20% at New Mountain), but cash burns persisted in biotech/small caps. Portfolio-level: Margin expansion rare (ClearPoint +400bps to 64%), outliers in revenue surges signal growth pockets vs sector stagnation risks.

20 high priority 30 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — May 13, 2026

Across 50 filings dominated by neutral 13F-HR disclosures from institutions like Third Avenue Management (heavy industrials exposure: Tidewater $77M, Valaris $50M, Boise Cascade $43M) and SouthernSun (Louisiana-Pacific $35M, Crane NXT $32M), portfolio snapshots reveal stable conviction in select S&P 500 Industrials amid tech-heavy allocations, with TRUSTCO BANK holding GE Aerospace ($6.7M). Operational 10-Q/8-K filings show mixed trends: revenue growth averaging +25% YoY in growth outliers like Shoulder Innovations (+65% to $16.7M Q1, guidance raised to $65-68M FY2026) and Pismo Coast Village (+13% to $2.2M), but sharp declines in biotechs like Aytu BioPharma (-33% Q3 revenue to $12.4M) and Semnur Pharma (opex +588% YoY). Banking peers reported robust net income gains (Finward +393% to $2.2M, Embassy +29% to $3.7M, Auburn +44% to $2.2M) driven by NII expansion (avg +13% YoY), though comprehensive losses from securities unrealized hits persist. Capital allocation highlights shareholder returns via NB Bancorp's completed 5% buyback (avg $20.96/share, cumulative 16% since 2025) and Embassy's $3M treasury repurchases. Forward catalysts include Shoulder FY guidance upgrade (37-44% growth), Inovio PDUFA Oct 30 2026, and XCF ops restart June 2026, signaling selective industrials/biotech alpha amid broader stability.

10 high priority 40 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 13, 2026

Across the 7 filings in the USA S&P 500 Energy intelligence stream, only Devon Energy provides direct sector exposure via its $475M stake in Waterbridge Infrastructure, signaling conviction in energy infrastructure amid neutral institutional 13F snapshots from managers favoring tech and industrials. Period-over-period trends in 10-Q filers reveal volatility: KAANAPALI LAND exploded with +4,529% YoY revenue to $20.4k from property sales, Winchester Bancorp posted +44% YoY net interest income and +11.4% assets, while Hughes Satellite saw -11.2% revenue but narrowed losses dramatically. Mixed sentiments dominate (3/4 applicable), with no insider trading activity disclosed, limited capital allocation (e.g., KAANAPALI's $981 distribution), and no forward-looking guidance except Hughes' going concern warning. Portfolio-level patterns show institutions maintaining diversified, tech-heavy positions with no major shifts QoQ/YOY. Key implication: Sparse direct energy insights, but Devon's outsized Waterbridge holding flags infrastructure opportunity; monitor non-energy filers for broader market spillovers into energy via capital flows. Overall, bullish turnarounds in KAANAPALI/Winchester contrast Hughes' distress, urging selective positioning.

3 high priority 4 medium 7 total filings
· daily

US Material Events SEC 8-K Filings — May 13, 2026

Across 50 SEC filings from May 13, 2026, dominant themes include strong shareholder approval at annual meetings (e.g., 15+ companies with >90% support for directors/auditors), mixed Q1/FY2026 earnings with biotech/pharma showing robust revenue growth (avg +50% YoY in 5 reporters like Aquestive +66%, Eos +445%) offset by consumer declines (Jack in the Box -4.3% rev YoY, Prestige -4.3%), and heightened M&A activity including Allegiant's $140M synergy acquisition of Sun Country. Capital allocation trends favor shareholder returns (Hanover $700M buyback) and debt optimization (Las Vegas Sands refinancing $1B notes, Tempus $350M convertibles). Executive churn signals caution (HF Sinclair CFO termination, Rent the Runway CEO departure) amid positive appointments and expansions (Applied Opto lease, Venu amphitheater). Period-over-period, margins compressed in 4/8 earnings reporters (avg -200bps, e.g., Jack in the Box 16.4% vs 19.6%), but cash flows improved in 6/10 (Doximity +19% FCF). Portfolio-level, biotech outperforms with trial catalysts, while SPACs extend deadlines (7 filings), pointing to prolonged deal hunts. Market implications: Favor growth biotechs and M&A plays, monitor consumer weakness and governance stability.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 13, 2026

The 50 filings for USA Dow Jones 30 stream, dominated by 13F-HR disclosures from institutions managing trillions in AUM, reveal overwhelming conviction in DJIA mega-cap tech leaders like Apple (top holding in 20+ filings, e.g., First Citizens $153B, Visionary $101M), Amazon, Alphabet, Nvidia, and Microsoft, with select QoQ share increases (e.g., Alesco +5.4% AAPL, +2.3% AMZN). Operational 10-Q/8-K filings show mixed Q1 2026 results across non-DJIA names: robust growth in energy (NGS rental rev +21% YoY, EBITDA guide to $92.5-97.5M), airlines (ALGT Sun Country acquisition, $140M synergies), and tech (Cisco rev +12% YoY to $15.8B, FY guide $62.8-63B; Identiv +40.7% rev), but persistent cash burn and losses in biotechs (Acrivon op ex down 8% YoY but cash use +5%; Aquestive cash to $110M). Capital allocation trends favor returns: NGS div +36% to $0.15, NB Bancorp completed buybacks of 16% shares since IPO at $19.25 avg, Cisco $0.42 div. Forward guidance largely raised/reaffirmed (5/7 cases), signaling resilience amid margin pressures (e.g., Cisco gross margin -200bps to 63.6%). Portfolio-level patterns highlight tech overweight (60%+ top holdings), energy/mining adds (Kopernik +4.2% NovaGold), and fixed income ETF tilts for defense.

12 high priority 38 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — May 13, 2026

Across 50 SEC filings for May 13, 2026, key themes include robust SPAC activity with multiple IPOs (Starlink AI, West Enclave) raising $200M+ and extensions (Aquaron, GP-Act III), signaling renewed M&A appetite in a potentially frothy market. Q1 2026 10-Qs reveal polarized performance: 14/22 reporting companies posted YoY revenue growth averaging 85% (outliers like SS Innovations +117%, SOLV Energy +66%), but 18/22 widened net losses amid SG&A surges (e.g., SOLV non-cash comp +8,300%), highlighting growth-at-all-costs in small caps/biotechs. Annual meetings (10+ filings) overwhelmingly passed director elections, say-on-pay, and auditor ratifications with >90% support, indicating stable governance. Biotech/health firms (Anteris, Azitra, Zenas) advanced trials with capital raises extending runways to 2029, while consumer/retail showed resilience (National Vision +6.6% rev, +4.4% comp sales). Capital allocation leans shareholder-friendly: Expensify $25M tender, News Corp $1B buyback authorization. Portfolio-level: Margin expansion rare (National Vision +150bps adj op margin), but cash burns average $4M/Q in loss-makers; forward catalysts cluster in H2 2026 trials/data readouts. Implications: Favor disciplined growers like National Vision/Cigna; monitor SPAC redemptions and biotech burn rates for downside risks.

31 high priority 19 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 13, 2026

The 50 filings, dominated by 13F-HR reports from institutions managing trillions in AUM, reveal unwavering conviction in S&P 500 Consumer Discretionary mega-caps like Apple (e.g., First Citizens $153.7B position, Martingale $55.4M), Amazon ($62.6B First Citizens, $140M NewEdge), and Alphabet ($233M NewEdge Cl A), with stable Q1 2026 portfolios across 30+ filers signaling no major rotations out of consumer tech/retail leaders. Retail operators show sales headwinds (Fossil -3.6% YoY to $224.8M, Lulus -10% to $57.5M) but resilient margins (Fossil gross 59.9%, op margin 5.4% swing to profit) and cost discipline (Fossil SG&A -9.9%, Lulus inventory -17%), narrowing losses amid FY guidance for positive EBITDA (Lulus) and 3-5% adj margins (Fossil). Key catalysts include FedEx Freight spin-off (record May 15, trading June 1 2026, 80.1% dividend distribution unlocking $4.1B value) and Las Vegas Sands $1B debt refi (higher 5.3-5.65% rates vs 3.5%). Mixed financials/funds (e.g., Bogota NI -3.4% YoY, Finward +393%) hold consumer exposure, while crypto ETFs (Canary suite) post sharp NAV declines (XRP -18% QoQ, Solana -40.5%) on unrealized depreciation. No notable insider trades or buybacks; capital allocation leans to distributions (e.g., New Mountain $8.9M up YoY) and debt management. Portfolio-level trend: Steady institutional overweight in consumer discretionary amid ops challenges implies defensive positioning for H2 2026 recovery.

19 high priority 31 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 13, 2026

Across 50 filings in the S&P 500 Healthcare intelligence stream dated May 13, 2026, direct operational updates from biotechs and providers reveal mixed Q1 2026 results with 7/9 healthcare firms showing narrowed net losses YoY (avg improvement ~40%) amid revenue ramps in select names like Precigen (+$21.9M YoY from near-zero on PAPZIMEOS launch) and Precision Optics (+108% YoY revenues), though cash burns persist and some revenues declined (e.g., CareView -2% YoY). 35+ 13F-HR filings from institutions like Merck, J&J, and others disclose stable holdings in healthcare/biotechs (e.g., Merck's $117M Moderna, J&J's $258M Protagonist), signaling sustained conviction without reported changes QoQ. Positive shareholder meetings at Vertex (97% avg director approval), Elevance Health, and others contrast proxy risks at Pacira; forward catalysts cluster in H2 2026 (PDUFAs, ASCO data). Capital allocation lean: dividends steady (e.g., Tri-County +12% YoY), no major buybacks noted in health filers. Portfolio-level trend: biotechs prioritizing commercialization (payer coverage expansions, J-codes) over R&D (avg -25% YoY spend), positioning for 2027 revenue inflection but risking near-term dilution.

19 high priority 31 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 13, 2026

Across 14 DEF 14A proxy statements filed around May 13, 2026, for US companies primarily holding annual meetings in June 2026, dominant themes include routine director elections (12/14 filings), advisory votes on executive compensation (9/14), auditor ratifications (8/14), and equity incentive plan expansions (e.g., BOX +7.2M shares, Oxford +750K shares, HealthEquity amended EIP), signaling expectations of future growth and talent retention amid strong governance emphasis (e.g., BOX 7/8 independent directors, Kroger all but CEO/Chair independent). Period-over-period trends are sparse but revealing: Kroger reported nearly doubled identical sales ex-fuel and 9% EPS growth in 2025 with eCommerce profitability at $16B, planning 30% new store growth in 2026 (positive outlier), while Bunker Hill Mining saw net losses widen sharply to $(90.4M) in 2025 from $(29.2M) in 2024 despite 14% YoY PEO compensation increase and TSR up to $140 (mixed signal). Other highlights include M3-Brigade's high-materiality SPAC merger with $500M PIPE (post-close PIPE owns 55%), AudioEye's 99% Say-on-Pay approval with 100% equity director comp, and leadership transitions (e.g., Perma-Pipe 3 resignations, Oxford director retirement at 72). Portfolio-level patterns show tech/cloud firms (BOX, SentinelOne, Marvell) prioritizing board stability and equity pools, retail (Kroger, Oxford) highlighting performance/governance, and small-caps/mining (Bunker Hill, SKYX) disclosing comp details amid volatility. Market implications favor monitoring June votes for comp/equity approvals as sentiment gauges, with bullish retail catalysts offsetting dilution risks in micro-caps like Classover (2.5B Class B authorization). No widespread insider selling noted, but equity-heavy comp (e.g., AudioEye RSU holdings up to 102K vested) indicates alignment.

14 high priority 14 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 13, 2026

The IPO Pipeline stream shows two key filings on May 13, 2026: USA Rare Earth (USAR) S-4 for a strategic merger with Texas Mineral Resources Corp. (TMRC), carrying positive sentiment and high materiality (9/10), and Nauticus Robotics S-1 for resale of up to 103.7M shares under a $250M facility, mixed sentiment (8/10 materiality) amid dilution risks. No direct YoY/QoQ financial trends available in these registration statements, but USAR's merger implies consolidation potential in rare earths with a fixed 3.82M share pool exchange. Nauticus demonstrates recent positive trend in Nasdaq compliance (regained Dec 19, 2025 after Oct 2025 deficiencies) but faces ongoing monitoring. Critical development: USAR-TMRC Q3 2026 closing catalyst post TMRC vote, offering de-SPAC-like path to public markets for TMRC. Portfolio-level pattern: 1/2 filings (50%) leverage mergers/S-1s for capital access/public listing in emerging sectors, highlighting small-cap reliance on dilutive/strategic structures amid regulatory hurdles.

2 high priority 2 total filings
· daily

Global High-Priority Regulatory Events — May 13, 2026

Across 50 pre-analyzed US SEC and global filings for May 13, 2026, mixed sentiment dominates (70% of filings), with stark contrasts between revenue growth in industrials/tech (e.g., Astronics +12% YoY sales, AmpliTech +49% revenue) and deepening losses/cash burns in biotechs/pharma (Semnur op ex +588% YoY) and crypto ETFs (NAV drops 18-40% QoQ amid unrealized depreciation). Period-over-period trends reveal portfolio-level margin compression averaging -100 bps in financials/REITs (LIC Housing NIM -5 bps, Bogota non-int inc -64% YoY), offset by capital returns like Cybertech's 2.73% buyback at ₹170/share and LIC's 500% dividend. Critical developments include Radhagobind's ongoing CIRP insolvency (8th COC meeting May 15), HF Sinclair CFO termination, and Nuvve's dilutive warrant exchange needing approval by July 27; crypto ETFs show crypto price sensitivity with Canary XRP/Solana NAV -18%/-40% QoQ. Sector themes highlight biotech cost-cutting (R&D -30-70% YoY in Spruce/Dermata) amid cash raises, while buybacks/dividends signal conviction in software/financials. Implications: Near-term alpha in buyback catalysts and turnarounds, but watch distress in microcaps/insolvencies for downside risks.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 13, 2026

Across 50 Q1 2026 10-Q filings, sentiment is predominantly mixed (38/50), with 6 negative and revenue growth averaging +25% YoY in outperformers like STAAR Surgical (+120%) and Astronics (+12%), but widespread margin compression (-150 bps avg in 12/20 operating cos) and cash burn in biotechs/pharma (e.g., Semnur op ex +588% YoY). Banks/insurers show resilience with net income +50% YoY avg (e.g., Avidbank +66%, UTG +81%), while crypto ETFs suffer massive unrealized depreciation (avg -25% NAV QoQ, e.g., Canary XRP -18%). Capital allocation leans conservative with buybacks/dividends in banks (Embassy repurchased $3M shares) amid rising debt in 15 cos (avg +10% QoQ). Portfolio trend: 22/50 cos improved op cash flow YoY, signaling working capital stabilization, but 18/50 deepened losses/stockholders' deficits. Key implication: Rotate to banks/turnarounds (Snail +operating income swing), avoid high-burn biotechs/crypto; watch leverage in trusts/REITs. No major guidance changes, but B&G Foods flags covenant risks.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — May 13, 2026

Three Nasdaq Capital Market small-cap companies disclosed critical listing compliance failures in 8-K filings around May 13, 2026, signaling heightened delisting risks amid governance lapses and share price weakness. CEA Industries violated Rule 5620(a) by failing to hold an annual shareholders' meeting within 12 months of FYE April 30, 2026, with a 45-day compliance plan deadline to June 22 and potential 180-day extension to October 27. Intrusion Inc. breached Rule 5550(a)(2) with closing bid prices below $1.00 for 30 consecutive trading days from March 25 to May 6, 2026, entering a 180-day grace period to November 3 with possible further extension via reverse split plan. Reviva Pharmaceuticals faces immediate delisting after missing its final bid price compliance deadline on May 11, with trading suspension at Nasdaq open on May 14, 2026, and shift to OTCQB under RVPH. Overarching themes include persistent QoQ share price declines (e.g., 30-day streak below $1), governance deterioration, and negative sentiment (all filings scored negative, avg materiality 9.3/10), with no bullish period-over-period trends evident. Portfolio-level implications: Increased volatility, liquidity evaporation, and short opportunities in Nasdaq small caps; no insider activity, capital allocation, or financial ratio improvements noted across filings.

3 high priority 3 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 13, 2026

Across 34 filings in the USA Corporate Distress & Bankruptcy stream, a mixed landscape emerges with 4 prominent Nasdaq compliance failures signaling acute distress (delisting risks for CEA Industries, Intrusion, Reviva, Ryvyl), offset by robust revenue growth in biotechs and energy firms (e.g., Aquestive +66% YoY, Eos +445% YoY, Allogene R&D expenses -36% YoY). Period-over-period trends show revenue expansion in 7/34 companies (avg +100% YoY where reported) but persistent losses narrowing in 4 cases, alongside heavy dilution from equity offerings/ATM (Nuvve 55% shares, iSpecimen, CEL-SCI) and debt refinancings (Tempus $350M notes, LVS $1B notes). Capital allocation leans toward financings (12 new facilities/offerings) and buybacks ($206M total in Prestige/ACV), with M&A/acquisitions in 5 firms indicating strategic pivots amid distress. Portfolio-level patterns highlight small-cap Nasdaq vulnerabilities (3/34 bid price/annual meeting issues) and biotech resilience (positive trials/guidance in Allogene/Aquestive/Armata), but overall sentiment skews mixed/neutral with 10/34 filings showing dilution risks. Critical implications include near-term catalysts like Nuvve stockholder vote (Jul 27) and Reviva delisting (May 14), urging monitors for liquidity crunches in distressed names.

34 high priority 34 total filings
· daily

US Executive Officer Management Changes SEC — May 13, 2026

Across 41 filings on USA Executive & Director Changes from May 13, 2026, the dominant theme is orderly leadership transitions, with 12 CEO/CFO/COO changes (e.g., HF Sinclair CFO terminated after leave, Power Solutions CEO resignation to interim CFO, Rent the Runway CEO to interim), 15+ successful annual meetings approving directors (90-99% support), comp plans, and auditors, signaling strong shareholder alignment. Financial reporters show mixed period trends: Doximity FY2026 revenue +13% YoY to $644.9M but Q4 net income -69% to $19.1M; Jack in the Box Q2 revenue -4.3% YoY, SSS -3.8%, margins -320 bps; Tango Q1 net loss +14% to $45.5M despite cash runway to 2028; Zenas Q1 net loss widened to $81M on +73% R&D. Capital allocation remains shareholder-friendly with Hanover's $700M buyback (replacing $63M remainder), Coeur's inaugural $0.02/share dividend (record May 22), and multiple LTIPs approved (e.g., MDU +6.5M shares). Positive sentiments dominate (22/41 positive, 10 neutral), with biotech/pharma showing clinical catalysts (Zenas BLA Q2 2026) amid leadership refreshes, implying sector rotation opportunities but watch CFO turnover (6 cases) for finance risks.

41 high priority 41 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 13, 2026

Across 41 SEC filings on USA Board Room Changes from May 13, 2026, the dominant theme is high C-suite and board turnover, with 12 CEO/CFO/president departures or transitions (e.g., HF Sinclair CFO termination, Power Solutions CEO resignation, Rent the Runway CEO step-down) amid neutral-to-negative sentiment, signaling potential instability in energy, pharma, and tech sectors. Annual shareholder meetings (15 filings) overwhelmingly passed director elections, auditor ratifications, and equity plans with 90-99% support (e.g., Vertex 94-99%, MDU >90%), reinforcing governance stability. Period-over-period trends show mixed financials: revenue growth in Doximity (+13% FY2026 YoY to $644.9M) and cash runway extensions (Tango to 2028, Zenas to Q2 2029), but margin compression in consumer names (Jack in the Box Restaurant-Level Margin -320 bps YoY to 16.4%) and widening losses in biopharma (Tango net loss +14% to $45.5M, Zenas +141% to $81M). Capital allocation leans bullish with Hanover's $700M buyback authorization (+$637M vs prior remainder), Coeur Mining's inaugural $0.02/share dividend, and LTIP expansions (e.g., MDU +6.56M shares). Forward-looking catalysts cluster in pharma (e.g., Zenas BLA Q2 2026, Tango data readouts 2026), while leadership promotions signal continuity (e.g., Toll Brothers EVP to President). Portfolio implication: Favor stable boards with buybacks/dividends; avoid high-turnover firms until interim stability proven.

41 high priority 41 total filings